score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6027	297.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Putatively Actionable	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	109.0	0.5596	1.0	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	MEL-IPI_Pat90-Normal-SM-4NFWM
Putatively Actionable	Preclinical			Copy Number	MDM2	Amplification				0.0	0.0		Putatively Actionable	nutlin-3	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.	https://doi.org/10.1111/j.1349-7006.2010.01821.x												0				MDM2 Amplification	0.0	MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2A Deletion		MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	
Putatively Actionable	Preclinical			Copy Number	CDKN2B	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2B Deletion		MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	
Investigate Actionability - High	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.I111M	0.4118	153.0	0.0	0.0		Investigate Actionability - High	Selumetinib	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability - High	Selumetinib	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106						0	246.0	0.4268	1.0	MAP2K1 p.I111M (Missense)	0.0	MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	MEL-IPI_Pat90-Normal-SM-4NFWM
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat90		
Investigate Actionability - Low	Clinical evidence		Inferential	Somatic Variant	PALB2	Missense	p.P249S	0.4584	397.0	0.0	0.0		Investigate Actionability - Low	Platinum	Chemotherapy	When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. 	Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.	https://doi.org/10.1038/nature14169							Investigate Actionability - Low	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	124.0	0.4113	1.0	PALB2 p.P249S (Missense)		MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	MEL-IPI_Pat90-Normal-SM-4NFWM
Investigate Actionability - Low			Clinical evidence	Somatic Variant	BLM	Missense	p.P715S	0.425	200.0	0.0	0.0														Investigate Actionability - Low	0.0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060	0	86.0	0.5116	1.0	BLM p.P715S (Missense)		MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	MEL-IPI_Pat90-Normal-SM-4NFWM
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A1774V	0.7384	237.0	0.0	0.0																			0	0.0	0.0	0.0	ROS1 p.A1774V (Missense)		MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	MEL-IPI_Pat90-Normal-SM-4NFWM
Biologically Relevant				Copy Number	KRAS	Amplification				0.0	0.0																			0				KRAS Amplification		MEL-IPI_Pat90	MEL-IPI_Pat90-Tumor-SM-4DK3G	
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.802																							0				COSMIC Signature 7 (80%)		MEL-IPI_Pat90		
